

Supplementary Table S2. Clinicopathological characteristics according to viable tumor size

	≤ 2 cm (n=34, 23.9%)	2-5 cm (n=44, 31.0%)	5-10 cm (n=50, 35.2%)	> 10 cm (n=14, 9.9%)	p-value
Clinical findings					
Age ≥60 yr	21 (61.8)	23 (52.3)	20 (40.0)	9 (64.3)	.319
Sex (male/female)	28 (82.4)/6 (17.6)	34 (77.3)/10 (22.7)	34 (68.0)/16 (32.0)	14 (100)/0 (0)	.986
B-viral etiology	30 (88.2)	36 (81.8)	38 (76.0)	8 (57.1)	.020
Preoperative locoregional treatment	23 (67.6)	17 (38.6)	14 (28.0)	0 (0.0)	<.001
Serum AFP ≥1,000 ng/mL	4 (11.8)	10 (22.7)	17 (34.0)	5 (35.7)	.016
Serum PIVKA-II level ≥200 mAU/mL (n=120)	5/29 (17.2)	9/35 (25.7)	34/43 (79.1)	12/13 (92.3)	<.001
Pathological findings					
Gross type 2	19 (55.9)	22 (50.0)	22 (44.0)	11 (78.6)	.713
Necrosis (present)	18 (52.9)	14 (31.8)	14 (28.0)	3 (21.4)	.014
Extent of necrosis (%) (n=49)	72.5 (10.0–99.0)	36.5 (1.0–90.0)	65.0 (1.0–80.0)	40.0 (40.0–40.0)	.091
Edmondson-Steiner grade III or IV	19 (55.9)	33 (75.0)	37 (74.0)	11 (78.6)	.080
Microvascular invasion (present)	7 (20.6)	15 (34.1)	25 (50.0)	6 (42.9)	.013
Major vessel invasion (present)	3 (8.8)	6 (13.6)	7 (14.0)	4 (28.6)	.139
Underlying cirrhosis (present)	29 (85.3)	33 (75.0)	31 (62.0)	4 (28.6)	<.001
pT category					<.001
pT1a	31 (91.2)	0 (0.0)	0 (0.0)	0 (0.0)	
pT1b	0 (0.0)	25 (56.8)	21 (42.0)	6 (42.9)	
pT2	0 (0.0)	13 (29.5)	22 (44.0)	4 (28.6)	
pT4	3 (8.8)	6 (13.6)	7 (14.0)	4 (28.6)	
CK19 positivity (n=112)	3/19 (15.8)	3/36 (8.3)	3/43 (7.0)	1/14 (7.1)	.341

Values are presented as median (range) or number (%).

AFP, α -fetoprotein; PIVKA-II, prothrombin induced by vitamin K absence-II; CK19, cytokeratin 19.